Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
A multicentre, randomized, open-label, parallel-group, active controlled study.
Primary hepatocellular carcinoma (HCC) is one of the most common types of cancer and accounts
 for significant morbidity and mortality worldwide. Notably, more than half of the new HCC
 cases and deaths develop in China. Transarterial chemoembolization (TACE) has been proposed
 as the first-line therapeutic strategy for the treatment of patients with unresectable HCC.
 However, TACE has several limitations itself which might be potentially associated with tumor
 metastasis and relapse.

 Recent studies have demonstrated that arsenic trioxide (As2O3) can act as the first-line
 therapeutic option in the treatment of acute promyelocytic leukemia. Thereafter, several
 small studies in China showed promising clinical benefits when As2O3 is administrated among
 the HCC patients. With these preliminary results, the investigators are planning to carry out
 a multicenter randomized controlled trial through which to explore the potential efficacy and
 safety of adjuvant As2O3 treatment for HCC patients.
1. Subject is 18-80 years old.

 2. Subject has no portal stem vein tumor thrombus.

 3. Subject has primary middle-advanced liver cancer of Barcelona Clinic Liver Cancer
 stages B/C inappropriate for surgical resection or other locoregional therapy and
 still presents with tumor lesions in the liver.

 4. Subject has evaluable tumor lesion(s) (using Magnetic Resonance Imaging /Computed
 Tomography) according to modified Response Evaluation Criteria in Solid Tumors
 (mRECIST) Version 1.1: single lesion size ≥5cm or at least one lesion of >3cm in size
 when 2-3 lesions exist or there are 4 or more lesions.

 5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤1,
 Fibrosis index based on 4 factors (FIB-4)≤6 and an expected survival time of 12 weeks
 or more.

 6. Haematology: white blood cell count ≥3.0×10^9/L; hemoglobin≥10 g/dL; blood platelet
 count≥80×10^9/L

 7. Blood biochemistry: serum albumin ≥2.8 g/dL, total bilirubin ≤2 mg/dL or ≤34.2 umol/L,
 alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 times of upper
 limit of normal (ULN); amylase and lipase ≤ 1.5 times of ULN; serum creatinine ≤2.0
 mg/dL or < 1.5 times of ULN; estimated creatinine clearance ≥60 mL/min.

 8. International normalized ratio (INR) is ≤ 2.3 or prothrombin time (PT) is ≤3 seconds
 than upper limit of normal control.

 9. Echocardiogram indicated a left ventricular ejection fraction (LVEF) of >50%.

 10. Subject has a liver function Child-Pugh class A or B.

 11. Subject is not pregnant or lactating.

 12. Female subjects must be infertile or agree to take effective contraceptives; male
 subjects and their partners of reproductive potential must also agree to use
 appropriate contraceptives.

 13. Subject had no second tumor in the last 5 years, excluding skin basal cell carcinoma
 or skin squamous carcinoma or any other carcinoma in situ.

 14. Subject had no history of systemic chemotherapy.

 15. Subject has no any other concomitant anticancer therapies, such as local radiotherapy,
 systemic chemotherapy and molecular targeted therapy.

 16. Subject and (or) guardian is able to understand this study and willing to provide
 written, informed consent to participate in this clinical study.